The Interleukin 8 pipeline drugs market research report outlays comprehensive information on the Interleukin 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 8 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Interleukin 8 - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers products from therapy areas such as Oncology, Infectious Disease, Immunology, and Dermatology which include the indications Solid Tumor, Renal Cell Carcinoma, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Inflammation, Chronic Inflammation, and Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome). It also reviews key players involved in Interleukin 8 targeted therapeutics development with respective active and dormant or discontinued products.

The Interleukin 8 pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 4, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Interleukin 8 overview

Interleukin 8 (CXCL8) is a member of the CXC chemokine family which plays an important role in neutrophil activation. CXCL8 is secreted by mononuclear macrophages, neutrophils, eosinophils, T lymphocytes, epithelial cells, and fibroblasts. G-protein heterotrimer (alpha, beta, gamma subunits) binds to CXCR1/CXCR2 receptor and activation by IL8 leads to gamma and beta subunits release from Galpha (GNAI2 in neutrophils) and activation of several downstream signaling pathways including PI3K and MAPK pathways.

For a complete picture of Interleukin 8’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.